Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older experiencing ADRs related to IVIG infusions~* Stable dose of IVIG for 3 months~* Willing to comply with all aspects of the protocol, including blood draws~* Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. Acceptable forms of contraception are defined as those with a failure rate \< 1% when properly applied and include: a combination oral pill, some intra-uterine devices, and a sterilized partner in a stable relationship. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire study period.~Exclusion Criteria:~* Receiving treatment for HAE, either prophylactic or acute therapy~* Patients with medical history of allergy to rabbits or rabbit-derived products (including rhC1INH)~* Patients who are pregnant, or breastfeeding, or are currently intending to become pregnant.~* Patients who, in the investigator's opinion, might not be suitable for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-esterase inhibitor [recombinant] (C1-INH-R) (Type: EXPERIMENTAL): Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:~* 6 - 8 weeks - subjects will receive 2 infusions of IVIG~* 9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).